Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of bolus-only Revasc (desirudin) in elective PCI
2009-010903-98Phase 2Completed
- Sponsor
- Canyon Pharmaceuticals
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of desirudin in coronary arteriosclerosis (4 arms), sponsored by Canyon Pharmaceuticals. Primary endpoint: Composite ischemic endpoint and major bleeding. Started Jun 2009; status: completed.
02
Drugs
desirudin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2009-010903-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010903-98.